Searched for
MYLAN DIABETIC DRUG
US FDA restricts imports of some Viatris drugs made at India facilityViatris has revealed that the FDA has restricted imports of 11 products made at its Indian facility after an inspection found violations of...- USFDA issues CRL for Bevacizumab license application moved by Viatris: Biocon"The USFDA has issued a CRL for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan)," a company sp...
- PLI scheme for pharma to benefit 55 firms, says CentreThe first category included biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, cell-based or gene th...
- Biocon Biologics launches Semglee, drug to control high blood sugar, in USTo encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of $147.98...
- Biocon gets US FDA nod to launch insulin glargineThe product branded as Semglee has an identical amino acid sequence to Sanofi’s Lantus® and is approved for the same indications. This is t...
- Biocon's partner Mylan gets favourable ruling from US patent authority for 4 devices"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. Thi...
- Biocon sees a sweet spot with its affordable insulin in USThe biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...
- Temasek, TrueNorth-CPPIB seek to invest in Biocon BiologicsEye minority stake in Biocon Biologics; unit may be valued at $4 billion, higher than the market cap of Biocon.
- Mylan-Biocon’s insulin biosimilar faces FDA hurdleFirms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.
- US generics probe reveals startling detail of price fixing in Doxycycline and GlyburideA Bloomberg report said two executives of Heritage Pharma – the US arm of Indian drug maker Emcure - are preparing to plead guilty to price...
- European Medicines Agency accepts marketing application of Biocon, Mylan productMylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.
- India makes all Mylan HIV drugs for developing world: Rajiv Malik, President, MylanWe were second to enter the US in the marketing of a generic version of AstraZeneca's heartburn drug Nexium, but we still managed to build ...
- Biocon, Mylan drug discovery programme to treat cancer, arthritis makes progressBiocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...
- Sun Pharma gets FDA nod for generic version of JanuviaThis comes as a surprise as Sun has partnered the US based MSD in the domestic market to sue Glenmark for the patent infringement on the sa...
- Biocon Inks Pact with Mylan for generic insulinIn 2009, Mylan and Biocon had come together to develop five blockbuster biologic drugs in cancer and pain areas.
- Ranbaxy Laboratories launches authorized generic Actos in USRanbaxy has launched authorized pioglitazone hydrochloride tablets, generic version of Takeda's diabetes drug sold under the brand Actos in...
- Windfall likely for Ranbaxy Laboratories after FDA says no to Watson PharmaceuticalsThe US drug regulator's refusal to allow Watson Pharma to launch generic version of diabetes drug could mean windfall for Ranbaxy, accordin...
- Mylan Laboratories looks for partners to launch drugsMatrix Laboratories, which was acquired by Mylan , is exploring new partnerships in India to launch about 100 products.
- Ranbaxy settles drug dispute with Takeda, US launch in 2012Ranbaxy Laboratories Ltd on Monday said it has entered into an agreement with the Japanese drug maker Takeda Pharmaceuticals for ending the...
- 'Basalog does not come under NPPA purview, NPPA should make the correction'Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...
Load More
